Determination Of Molecular Status And Benefit Of Use Fludeoxyglucose (18F-FDG) In PET/CT imagining In Juvenile Patients With Histiocytosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515895-11-00

Acronym

HISTIOGEN

Enrollment

150

Registered

2024-08-26

Start date

2021-04-15

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

histiocytic cell proliferation

Brief summary

EFS – (event-free survival).

Detailed description

PFS (Progression-Free Survival), OS (Overall Survival), ORR (Overall Response Rate), Reactivation rate after 2 years, Rate of participants presenting with Adverse Events separated by degree of intensity, category, affected organ or system.

Interventions

DRUGFludeoxyglucose (18F) Synektik

DRUG200-2200 MBq/ml

DRUGroztwór do wstrzykiwań

DRUGGLUNEKTIK

DRUG1 GBq/mL

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
EFS – (event-free survival).	—

Secondary

Measure	Time frame
PFS (Progression-Free Survival), OS (Overall Survival), ORR (Overall Response Rate), Reactivation rate after 2 years, Rate of participants presenting with Adverse Events separated by degree of intensity, category, affected organ or system.	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026